Skip to main content
INDP
NASDAQ Life Sciences

Indaptus Secures $24M via Private Placement at Nasdaq Minimum Price

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.11
Mkt Cap
$277.144M
52W Low
$0.92
52W High
$8.57
52W Position info
129% above low
Off High info
75% below high
Rel. Volume info
8.2× avg
Market data snapshot near publication time

INDP has more than doubled off its 52-week low of $0.92 on elevated volume (8.2× avg).

Summary

Indaptus Therapeutics agreed to sell 20.34 million shares for ~$24 million in a private placement priced at the Nasdaq Minimum Price plus $0.015, with proceeds earmarked for working capital and early-stage research into a sleep-related neurotechnology device.


Key Events · Financing and Capital Events · INDP

  • $24M Private Placement

    Indaptus agreed to sell 20,338,974 shares for approximately $24.0 million gross proceeds at the Nasdaq Minimum Price plus $0.015 per share.

  • ~15% Dilution

    With 133,242,324 shares outstanding before the deal, the new shares represent roughly 15% additional dilution to existing holders.

  • Strategic Pivot to Neurotechnology

    Proceeds may fund early-stage research and preclinical evaluation of a neurotechnology/neural-network-based device for sleep-related conditions, with a view toward a future FDA submission.

  • Going Concern Backdrop

    The company has no active clinical trials and a going concern warning; this capital extends runway but at a meaningful cost to existing shareholders.


Analysis · INDP · Life Sciences

On September 8, 2026, Indaptus entered into a stock purchase agreement to sell 20,338,974 shares for approximately $24.0 million in gross proceeds. The per-share price is the Nasdaq Minimum Price plus $0.015, which is the lower of the prior day's close or the five-day average close. With 133,242,324 shares outstanding before the deal, the new shares represent roughly 15% additional dilution. The company has no active clinical trials and a going concern warning, so this capital extends runway but comes at a meaningful cost to existing holders. The use of proceeds includes a pivot toward a neurotechnology device for sleep-related conditions, a notable strategic shift for a company that recently discontinued its Decoy20 program.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INDP was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.1M. The 52-week trading range was $0.92 to $8.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INDP - Latest Insights

INDP
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $3.32 info
Change: +$0.220 (+7%) info
Market Cap: $509.961M info
INDP
Nov 13, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.17
Real-time Price: $3.32 info
Change: +$0.150 (+5%) info
Market Cap: $509.961M info
INDP
Nov 13, 2026, 8:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.15
Real-time Price: $3.32 info
Change: +$0.170 (+5%) info
Market Cap: $509.961M info
INDP
Aug 31, 2026, 9:25 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $3.32 info
Change: +$2.18 (+191%) info
Market Cap: $509.961M info
INDP
Aug 26, 2026, 4:35 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $3.32 info
Change: +$2.16 (+186%) info
Market Cap: $509.961M info